Drug manufacturer Takeda’s designated specialty pharmacy and distributor for its leukemia drug Iclusig is making 340B covered entities declare on a form whether they will opt in or opt out of 340B pricing on purchases, as a condition for obtaining Takeda’s drug.
The form says that, by selecting to obtain 340B pricing, the entity agrees to be billed “at the 340B acquisition cost for eligible purchased products,” and “shall comply with all applicable 340B requirements, including, but not limited to, submitting to manufacturer and government audits, completing required re-certifications, and protecting against diversion and duplicate discounts.”
Drug manufacturer Takeda’s designated specialty pharmacy and distributor for its leukemia drug Iclusig is making 340B covered entities declare on a form whether they will opt in or opt out of 340B pricing on purchases, as a condition for obtaining Takeda’s drug.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
